Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Purchases 3,912 Shares of Becton, Dickinson and Company $BDX

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its position in Becton, Dickinson and Company (NYSE:BDX) by 79.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,832 shares of the medical instruments supplier’s stock after acquiring an additional 3,912 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Becton, Dickinson and Company were worth $1,647,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. SOA Wealth Advisors LLC. grew its position in Becton, Dickinson and Company by 256.8% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 95 shares during the last quarter. Bell Investment Advisors Inc boosted its stake in Becton, Dickinson and Company by 474.1% during the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 128 shares in the last quarter. Bank of Jackson Hole Trust increased its holdings in Becton, Dickinson and Company by 85.6% in the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after buying an additional 95 shares during the period. CVA Family Office LLC raised its stake in shares of Becton, Dickinson and Company by 79.5% in the 2nd quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 97 shares in the last quarter. Finally, CoreFirst Bank & Trust bought a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth about $38,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on BDX shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Morgan Stanley boosted their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Wall Street Zen lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Argus lifted their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Finally, Bank of America increased their price target on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. Four research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and an average price target of $207.64.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $202.78 on Monday. Becton, Dickinson and Company has a twelve month low of $162.29 and a twelve month high of $251.99. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69. The company has a market cap of $57.77 billion, a P/E ratio of 34.78, a price-to-earnings-growth ratio of 2.24 and a beta of 0.23. The business’s fifty day moving average is $193.11 and its 200-day moving average is $188.36.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The firm had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th were issued a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.1%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date was Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio is currently 72.04%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 629 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $196.03, for a total value of $123,302.87. Following the completion of the transaction, the executive vice president owned 13,105 shares in the company, valued at $2,568,973.15. This trade represents a 4.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bertram L. Scott sold 217 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the transaction, the director directly owned 35,816 shares of the company’s stock, valued at $6,324,389.28. This trade represents a 0.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 1,052 shares of company stock worth $201,235. 0.40% of the stock is currently owned by insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.